The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 2 trial of trastuzumab and/or everolimus in hormone-resistant HER2-negative metastatic breast cancer.
Amelia Bruce Zelnak
No relevant relationships to disclose
Elisavet Paplomata
No relevant relationships to disclose
Sujatha Murali
No relevant relationships to disclose
Geetha D. Vallabhaneni
No relevant relationships to disclose
Virginia G. Kaklamani
Honoraria - Genentech; Novartis
Xiaoxian Li
No relevant relationships to disclose
Yuan Liu
No relevant relationships to disclose
Ruth O'Regan
Consultant or Advisory Role - Novartis
Research Funding - Genentech